Marisa Brizzi

Marisa Brizzi

Auto-generated profile, based on publicly available information

Marisa Brizzi

UC Health, Cincinnati, OH, USA

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 December 2024 in Journal of International Medical Research
Verified
Journal Article
Open access
MBMarisa B. Brizzi
Marisa B. Brizzi
TCTracy L. Cable
Tracy L. Cable
DPDimple C. Patel
Dimple C. Patel
KWKelli Williams
Kelli Williams
ZAZoe Adjei
Zoe Adjei
CFCarl J. Fichtenbaum
Carl J. Fichtenbaum
Antiretroviral (ARV) drug resistance poses a threat to ending the HIV epidemic. As the rates of integrase resistance continue to increase globally, the availability of options for HIV treatment becomes limited. Heavily treatment-experienced (HTE) people with HIV (PWH) are limited to two or fewer available fully active ARV classes and are more likely to have an AIDS-defining event. Appropriate identification and management of HTE PWH is crucial to improving patient outcomes and reducing the future spread of drug-resistant HIV. As treatment options become more limited owing to drug resistance, the availability of more potent drugs with a marked increase in virologic suppression is needed in the current ART era. The purpose of this narrative review is to review the identification of HTE PWH, novel mechanisms of resistance, and management of HTE PWH in resource-rich and resource-limited settings using novel ARVs and combination ART.

1 April 2023 in Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
Verified
Journal Article
Open access
MBMarisa Brizzi
Marisa Brizzi
ESElizabeth M. Sherman
Elizabeth M. Sherman
SGSarah B. Green
Sarah B. Green
DNDiana N. Nowicki
Diana N. Nowicki
EDEmily Drwiega
Emily Drwiega
Spencer DurhamSpencer Durham
Spencer Durham
The HIV epidemic continues to pose a significant burden on the healthcare system. Although the incidence of annual new infections is decreasing, health disparities persist and most new infections remain concentrated into different racial, ethnic, and minority groups. Pre‐exposure prophylaxis (PrEP), which involves those at high risk of acquiring HIV to take chronic medications to prevent acquisition of the virus, is key to preventing new HIV infections. The purpose of this article is to review medication therapies for PrEP and examine their role in personalizing PrEP in different patient populations. Additionally, new medications currently under development for PrEP are reviewed, as well as treatment as prevention (TasP) and post‐exposure prophylaxis (PEP). There are currently four medications available for PrEP: the oral options of co‐formulated emtricitabine/tenofovir disoproxil fumarate (FTC/TDF) or emtricitabine/tenofovir alafenamide (FTC/TAF); injectable long‐acting cabotegravir (CAB‐LA); and the vaginal ring dapivirine (DPV‐VR). FTC/TAF is not currently indicated for persons at risk for HIV through vaginal sex due to lack of studies, but trials are currently ongoing. DPV‐VR is available in Zimbabwe and South Africa and has been endorsed by the World Health Organization but is not currently available in the United States. Several agents are also in development for use in PrEP: the novel long‐acting injectable lenacapavir, a first‐in‐class capsid inhibitor, which has no cross‐resistance to any existing HIV drug class; the subdermal implant islatravir, a first‐in‐class translocation inhibitor; and VRC01, a broadly neutralizing antibody (bnAb) which has been evaluated in proof‐of‐concept studies that may lead to the development of more potent bnAbs. Overall, PrEP is highly effective at preventing HIV infection in high‐risk populations. Identifying optimal PrEP regimens in different patient populations is complex and must consider patient‐specific factors and medication cost and access considerations. Lastly, providers should consider individual patient preferences with regard to prevention to improve access, retention in care, and adherence.

22 May 2026 in Advances in Therapy
Verified
Journal Article
Open access
NHNeil Hawkins
Neil Hawkins
AHAniruddha Hazra
Aniruddha Hazra
MBMarisa Brizzi
Marisa Brizzi
JTJuliette Thompson
Juliette Thompson
RGRichard Grove
Richard Grove
LDLaure Dupont-Benjamin
Laure Dupont-Benjamin
Long-acting injectable cabotegravir (hereafter referred to as cabotegravir) is the first long-acting injectable approved for pre-exposure prophylaxis (PrEP) based on the HPTN 083 and 084 trials. Long-acting injectable lenacapavir (hereafter referred to as lenacapavir) was approved for PrEP based on the PURPOSE 1 and 2 trials. In the absence of a head-to-head trial, we conducted an indirect treatment comparison (ITC) to assess efficacy of lenacapavir versus cabotegravir in reducing the risk of HIV acquisition. A systematic literature review identified all relevant trials. Efficacy inputs for this ITC were derived from re-adjudicated data from the injection phase of the HPTN trials or published data from the PURPOSE trials. The ITC was performed using 2 network approaches: (1) using no PrEP and (2) using daily oral tenofovir disoproxil fumarate/emtricitabine (TDF/FTC) as common comparators, with adjustments accounting for differing levels of adherence to TDF/FTC across trials. Sensitivity analyses were also performed using data from both the oral lead-in and injection phases of the HPTN trials. Both network approaches estimated high and comparable efficacy of cabotegravir and lenacapavir. Using no PrEP (network approach 1), the base case estimated hazard ratio (95% CrI) of lenacapavir versus cabotegravir was 1.04 (0.19, 5.69) in men who have sex with men and transgender women and 0.00 (0.00, 3.21) in cisgender women. Predicted efficacy (95% CrI) rates of cabotegravir versus no PrEP were high in men who have sex with men and transgender women 96% (90%, 98%)] and cisgender women [98% (89%, 100%)] in the HPTN trials, which were comparable to the PURPOSE trials [men and gender-diverse people, 96% (82%, 99%); cisgender women, 100%(96%,100%)]. Sensitivity analyses confirmed these findings. Based on this ITC, cabotegravir and lenacapavir offer similar and high efficacy in preventing HIV acquisitions compared with no PrEP or TDF/FTC. Graphical abstract and video abstract available for this article.

8 January 2026 in JACCP: Journal of the American College of Clinical Pharmacy
Verified
Journal Article
Closed access
RPRadhika S. Polisetty
Radhika S. Polisetty
Spencer DurhamSpencer Durham
Spencer Durham
RRRoxane Rohani
Roxane Rohani
ACAshley Cluck
Ashley Cluck
ESElizabeth Sherman
Elizabeth Sherman
KSKristy Shaeer
Kristy Shaeer

23 December 2023 in American Journal of Health-System Pharmacy
Verified
Journal Article
Closed access
PDF file
KMKevin J Mercer
Kevin J Mercer
MBMarisa B Brizzi
Marisa B Brizzi
DBDevon N Burhoe
Devon N Burhoe
JSJoshua M Senn
Joshua M Senn
RRRoxane Rohani
Roxane Rohani
Spencer DurhamSpencer Durham
Spencer Durham
Purpose: Sexually transmitted infections (STIs) continue to have a disproportionate impact on individuals belonging to sexual, gender, and racial minorities. Across the nation, many emergency medicine pharmacists (EMPs) possess the skills and knowledge to expand the provision of expedited partner therapy (EPT) for STIs and provide HIV prophylaxis within existing practice frameworks. This report serves as a call to action for expanded provision of EPT and HIV prophylaxis by EMPs and highlights current barriers and solutions to increase pharmacist involvement in these practice areas. Summary: Emergency medicine pharmacy practice continues to expand to allow for limited prescribing authority through collaborative practice agreements (CPAs). In recent years, CPA restrictions have been changed to facilitate treatment of more patients with less bureaucracy. This report addresses the unique challenges and opportunities for expanding EPT and HIV pre- and postexposure prophylaxis provision by pharmacists in emergency departments (EDs). Furthermore, current strategies and treatments for EPT, such as patient-delivered partner therapy and HIV prophylaxis, are discussed. Pharmacist involvement in STI treatment and HIV prevention is a key strategy to increase access to high-risk populations with high ED utilization and help close current gaps in care. Conclusion: Expanding EMP provision of EPT and HIV prophylaxis may be beneficial to reducing the incidence of STIs and HIV infection in the community. CPAs offer a feasible solution to increase pharmacist involvement in the provision of these treatments. Legislative efforts to expand pharmacist scope of practice can also contribute to increasing access to EPT and HIV prophylaxis. With these efforts, EMPs can play an essential role in the fight against STIs and HIV.

27 September 2019 in International Journal of STD & AIDS
Verified
Journal Article
Closed access
PDF file
MBMarisa B Brizzi
Marisa B Brizzi
TCThomas D Chiampas
Thomas D Chiampas
SMSarah M Michienzi
Sarah M Michienzi
JYJeremy D Young
Jeremy D Young
MPMahesh C Patel
Mahesh C Patel
MBMelissa E Badowski
Melissa E Badowski
A trend of increased adverse effects and laboratory abnormalities was observed in patients treated at the University of Illinois Hospital and Health Sciences System (UIH) HIV Telemedicine Clinic after switching to abacavir/dolutegravir/lamivudine (ABC/DTG/3TC). Therefore, we sought to investigate if major clinical trials overestimated the safety and tolerability of DTG-based antiretroviral therapy (ART). This study was a single-center, retrospective, pre- and post-analysis of incarcerated patients receiving care at the UIH HIV Telemedicine Clinic, USA. Patients included were adults with HIV switched from previous ART to ABC/DTG/3TC. Primary endpoints included patient-reported adverse effects and changes in renal and hepatic function from baseline. A total of 95 patients were included in the study. After switching from previous ART to ABC/DTG/3TC, 20% of patients reported incidence of adverse effects. Most common were headache (7.4%), nausea (6.3%) rash (3.2%), fatigue (3.2%), and insomnia (2.1%). There were statistically significant increases in serum creatinine (SCr), in 20% of the patients (P < 0.0001), with a median increase of 0.38 mg/dl. ABC/DTG/3TC appears to have similar or fewer adverse effects in the real-world incarcerated population compared to clinical trials. DTG-based ART can cause statistically significant increases in SCr in some patients.